NEO - NeoGenomics, Inc.
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $17.46 and last traded at $17.37, with a volume of 1679789 shares. The stock had previously closed at $16.79. Analyst Ratings Changes Several equities analysts have commented on the
Valuation Assessment of NeoGenomics Inc (NEO)On August 26, 2026, NeoGenomics Inc (NEO) shares rose 3.5% today, closing at $17.37. The stock has experienced a no
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared with a 20% historical benchmark. The result was nearly 2.5 times the historical benchmark and was statistically significant at p=0.0047.
Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days — No major toxicities reported across the cohort; adverse events predominantly low-grade — Company to host investor conference call and webcast today at 8:30 a.m. Eastern Time CALABASAS, Calif.
Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
On July 31, 2026, NeoGenomics Inc (NEO) shares fell 3.7% to $15.29, reflecting a mixed price performance amid broader market movements. The stock has traded wit
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $16.10 and last traded at $15.5070, with a volume of 629708 shares changing hands. The stock had previously closed at $13.40. The medical research company reported
NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
American Capital Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ: NEO) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,250,878 shares of the medical research company's stock after selling 73,488 shares
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company's novel temozolomide-perillyl alcohol conjugate.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.